Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Purpose Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study.